Physician profile
David Chiu
NPI 1073594537
$69,453.41
in general payments reported to CMS, 2019-2025
35 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $6,897 · 2021: $3,846 · 2022: $3,750 · 2023: $4,659 · 2024: $1,228 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,529 · Travel and Lodging: $2,527 · Consulting Fee: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,529.24 |
| Travel and Lodging | $2,526.85 |
| Consulting Fee | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $51,079.12 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $11,006.65 | 2019-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $1,382.11 | 2023-2025 | |
| Janssen Research & Development, LLC | $1,218.98 | 2023 | |
| Shionogi INC | $1,082.94 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $495.00 | 2020 | |
| Amgen INC. | $427.37 | 2019-2025 | Repatha |
| Abbott Laboratories | $369.09 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $347.97 | 2021-2024 | |
| Ucb, INC. | $330.88 | 2019-2025 | Briviact, Rystiggo |
| Portola Pharmaceuticals, LLC | $248.79 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $220.48 | 2019-2024 | Xarelto |
| Avanir Pharmaceuticals, INC. | $185.99 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $163.10 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $157.06 | 2021-2023 | Ultomiris |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $125.22 | 2020-2025 | Bodyguardian |
| Csl Behring | $99.03 | 2020-2024 | Hizentra, Kcentra |
| Otsuka America Pharmaceutical, INC. | $82.92 | 2023-2024 | Nuedexta |
| Abbvie INC. | $63.90 | 2021-2025 | |
| Janssen Global Services, LLC | $44.08 | 2024 | |
| Chiesi USA, INC. | $36.19 | 2019-2020 | |
| Ge Healthcare | $31.73 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.09 | 2023 | Gammagard |
| Saol Therapeutics INC. | $28.99 | 2020 | |
| Springworks Therapeutics, INC. | $26.62 | 2025 | Gomekli |
| Novartis Pharmaceuticals Corporation | $21.91 | 2025 | |
| Esperion Therapeutics, INC. | $21.57 | 2022 | |
| Allergan, INC. | $18.43 | 2020 | |
| Strongbridge US INC. | $17.10 | 2020 | |
| Grt US Holding, INC. | $17.08 | 2020 | |
| Genzyme Corporation | $16.80 | 2019 | |
| Grifols USA, LLC | $15.41 | 2019 | |
| Amylyx Pharmaceuticals, INC. | $14.64 | 2023 | Relyvrio |
| Microtransponder, INC. | $13.83 | 2023 | |
| Biogen, INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.